Log in to save to my catalogue

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic col...

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic col...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2724089553

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer

Publication information

Publisher

New York: Nature Publishing Group US

More information

Scope and Contents

Contents

Anti-BRAF/EGFR therapy was recently approved for the treatment of metastatic
BRAF
V600E
colorectal cancer (mCRC
BRAF-V600E
). However, a large fraction of patients do not respond, underscoring the need to identify molecular determinants of treatment response. Using whole-exome sequencing in a discovery cohort of patients with mCRC

Alternative Titles

Full title

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2724089553

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2724089553

Other Identifiers

ISSN

1078-8956,1546-170X

E-ISSN

1546-170X

DOI

10.1038/s41591-022-01976-z

How to access this item